M&As this week: First Coin Capital, China Grand Pharmaceutical and Healthcare Holdings, Tael Management


Canadian technology services company First Coin Capital plans to acquire Bradmer Pharmaceuticals, a pharmaceutical company based in the US.

First Coin plans to raise C$10m ($7.97m) through the private placement of subscription receipts to fund the acquisition.

China Grand Pharmaceutical and Healthcare Holdings (formerly Maxx Bioscience Holdings) plans to acquire 22.8% stake in Chinese pharmaceutical company Shanxi Xin Beilin Medical from Huang Xiaohua.

The purchase consideration for the acquisition is CNY131.5m ($19.76m).

"China Grand Pharmaceutical and Healthcare Holdings (formerly Maxx Bioscience Holdings) plans to acquire 22.8% stake in Chinese pharmaceutical company Shanxi Xin Beilin Medical from Huang Xiaohua."

Tael Management (Singapore) (TAEL Two Partners) and David Ho Sue San (collectively joint offerors) plan to acquire the remaining stake in Malaysian pharmaceutical company Hovid Berhad for MYR243m ($57.31m).

The Singapore-based private equity firm plans to make the acquisition through Fajar Astoria Sdn Bhd, a special purpose vehicle.

Biopharmaceutical company Ligand Pharmaceuticals plans to acquire antibody discovery company Crystal Biosciences for $25m.

Both companies involved in the acquisition are based in the US.